Bailey M J, Gazet J C, Smith I E, Steel G G
Br J Cancer. 1980 Oct;42(4):530-6. doi: 10.1038/bjc.1980.276.
Five lines of human breast-carcinoma xenografts have been tested for sensitivity to cyclophosphamide, methotrexate, 5-fluorouracil, adriamycin, vincristine and melphalan, alone and in combination, using tumour growth delay as an end-point. The xenograft lines were established and passaged in mice immune-suppressed by thymectomy and whole-body irradiation. There was a considerable range of sensitivity of the different lines to the agents studied, and within this variation there was evidence that the most effective single agent or combination differed for each tumour. Combination chemotherapy was more effective than single agents in 3 of the lines, but melphalan was more effective than either combination in the other 2. It is suggested that a panel of human breast tumours grown in immune-suppressed mice may prove useful in testing new cytotoxic agents for activity against breast cancer before their use in clinical trials, and that more effective combinations of existing drugs might be designed with the aid of this system.
以肿瘤生长延迟作为终点,对五株人乳腺癌异种移植瘤进行了环磷酰胺、甲氨蝶呤、5-氟尿嘧啶、阿霉素、长春新碱和美法仑单药及联合用药敏感性的测试。这些异种移植瘤系在经胸腺切除和全身照射免疫抑制的小鼠体内建立并传代。不同株对所研究药物的敏感性范围相当大,在此变异范围内,有证据表明每种肿瘤最有效的单药或联合用药各不相同。联合化疗在三株中比单药更有效,但美法仑在另外两株中比联合用药更有效。有人提出,在免疫抑制小鼠体内生长的一组人乳腺肿瘤,可能在新的细胞毒性药物用于临床试验之前,对其抗乳腺癌活性的测试有用,并且借助该系统可能设计出更有效的现有药物联合方案。